Trimethylammonium

Trimethylammonium

SCHEMBL219375

C[NH+](C)C.FC(F)(F)c1cc([B-](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)(c2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc(C(F)(F)F)c1

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.38
IDO1 P14902 2/20 0.34
MAPT P10636 1/20 0.34
RAPGEF4 Q8WZA2 1/20 0.34
XPO1 O14980 1/20 0.32
PDE2A O00408 1/20 0.32
ADRB1 P08588 1/20 0.31
IKBKB O14920 1/20 0.31
RXRA P19793 2/20 0.31
RXRB P28702 2/20 0.31
ITGB3 P05106 1/20 0.31
ITGAV P06756 1/20 0.31
RXRG P48443 1/20 0.31
P2RX1 P51575 1/20 0.30
TMPRSS4 Q9NRS4 1/20 0.30
KIF11 P52732 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL41567 0.90 CES2 (0.44) CES2IDO1MAPTRAPGEF4XPO1
SCHEMBL30509222 0.88 CES2 (0.39) CES2IDO1MAPTRAPGEF4XPO1
SCHEMBL2451170 0.87 CES2 (0.42) CES2IDO1MAPTRAPGEF4XPO1
Ammonia Solution, Strong SCHEMBL4954250 0.87 CES2 (0.42) CES2IDO1MAPTRAPGEF4XPO1
Hydrochloric Acid SCHEMBL4429117 0.87 CES2 (0.42) CES2IDO1MAPTRAPGEF4XPO1
SCHEMBL8004410 0.87 CES2 (0.42) CES2IDO1MAPTRAPGEF4XPO1
SCHEMBL6866090 0.87 CES2 (0.42) CES2IDO1MAPTRAPGEF4XPO1
SCHEMBL3464534 0.87 CES2 (0.42) CES2IDO1MAPTRAPGEF4XPO1
SCHEMBL226082 0.87 CES2 (0.42) CES2IDO1MAPTRAPGEF4XPO1
SCHEMBL1451136 0.87 CES2 (0.42) CES2IDO1MAPTRAPGEF4XPO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 845 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114867758-B Metallocene and method thereof 埃克森美孚化学专利公司 2025-04-08 CN claimed
CN-113614123-B Transition metal bis (phenoxide) complexes and their use as olefin polymerization catalysts 埃克森美孚化学专利公司 2024-01-23 CN claimed
US-11760814-B2 1,5 diazabicyclooctane ligand systems and methods therewith EXXONMOBIL CHEMICAL PATENTS INC. (US) 2023-09-19 US claimed
EP-4222180-A1 BIS(HETEROCYCLIC-OLATE) LEWIS BASE CATALYSTS AND METHODS THEREOF ExxonMobil Chemical Patents Inc. (US) 2023-08-09 EP claimed
CN-116490528-A Polymer compositions containing cyclics obtained using transition metal bis (phenoxide) catalyst complexes and process for their preparation 埃克森美孚化学专利公司 2023-07-25 CN claimed
EP-4196507-A1 CYCLIC CONTAINING POLYMER COMPOSITIONS OBTAINED USING TRANSITION METAL BIS(PHENOLATE) CATALYST COMPLEXES AND PROCESS FOR PRODUCTION THEREOF ExxonMobil Chemical Patents Inc. (US) 2023-06-21 EP claimed
CN-113423744-B Lewis base catalyst and method thereof 埃克森美孚化学专利公司 2023-05-05 CN claimed
CN-113423742-B Bis (arylphenoxide) lewis base catalysts and methods thereof 埃克森美孚化学专利公司 2023-05-05 CN claimed
EP-4103629-A1 POLYETHYLENE COMPOSITIONS OBTAINED USING TRANSITION METAL BIS(PHENOLATE) CATALYST COMPLEXES AND HOMOGENEOUS PROCESS FOR PRODUCTION THEREOF ExxonMobil Chemical Patents Inc. (US) 2022-12-21 EP claimed
EP-4103630-A1 PROPYLENE COPOLYMERS OBTAINED USING TRANSITION METAL BIS(PHENOLATE) CATALYST COMPLEXES AND HOMOGENEOUS PROCESS FOR PRODUCTION THEREOF ExxonMobil Chemical Patents Inc. (US) 2022-12-21 EP claimed
WO-2005105864-A1 HETEROCYCLIC SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2005-11-10 WO claimed
US-20050239981-A1 Phosphorus bridged metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. 2005-10-27 US claimed
US-20050239980-A1 Phosphorus substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. 2005-10-27 US claimed
EP-1546223-A2 SUPERCRITICAL POLYMERIZATION PROCESS AND POLYMERS PRODUCED THEREFROM ExxonMobil Chemical Patents Inc. (US) 2005-06-29 EP claimed
EP-1521758-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION Exxonmobil Chemical Patents Inc. (US) 2005-04-13 EP claimed
US-20040266961-A1 Catalyst composition II EXXONMOBIL CHEMICAL PATENTS INC. 2004-12-30 US claimed
WO-2004026923-A9 SUPERCRITICAL POLYMERIZATION PROCESS AND POLYMERS PRODUCED THEREFROM EXXONMOBIL CHEM PATENTS INC (US) 2004-09-10 WO claimed
US-20040122191-A1 Supercritical polymerization process and polymers produced therefrom EXXONMOBIL CHEMICAL PATENTS INC 2004-06-24 US claimed
WO-2004026923-A2 SUPERCRITICAL POLYMERIZATION PROCESS AND POLYMERS PRODUCED THEREFROM EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-04-01 WO claimed
WO-2004007509-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-01-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11760814-B2 1,5 diazabicyclooctane ligand systems and methods therewith ODC1, DDT, OXGR1 CES2 1107/4885IDO1 145/4885MAPT 4240/4885
US-20050239981-A1 Phosphorus bridged metallocene compounds for olefin polymerization PYM1, ZNF207, POLL CES2 4308/4885IDO1 3042/4885MAPT 778/4885
US-20040266961-A1 Catalyst composition II MLX, CBX2, BMX CES2 1386/4885IDO1 652/4885MAPT 1902/4885
US-20050239980-A1 Phosphorus substituted metallocene compounds for olefin polymerization CCRL2, ARL1, OSBP2 CES2 2758/4885IDO1 3639/4885MAPT 3649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.